Overview of the Offering#
Rein Therapeutics, Inc. (NASDAQ:RNTX) has announced a public offering of 50 million shares of common stock priced at $1.00 per share. This price is lower than the current stock price of $1.35, reflecting an 18% decline in shares over the past week.
Financial Details#
The company expects to raise gross proceeds of $50 million before accounting for underwriting fees and other expenses. Additionally, the underwriters have a 45-day option to buy up to 7.5 million extra shares at the same price to manage any excess demand. The offering will close around May 4, 2026, pending standard closing conditions.
Use of Proceeds#
Rein Therapeutics plans to use the funds to support its ongoing Phase 2 clinical trial of LTI-03, a treatment for idiopathic pulmonary fibrosis, and for general corporate needs. The company believes that the net proceeds, along with its existing cash, will sustain its operations until 2028.
Company Background#
Rein Therapeutics specializes in developing treatments for rare lung diseases and fibrosis. Its leading candidate, LTI-03, is a synthetic peptide that has received Orphan Drug Designation in the U.S. for its potential to treat specific conditions. The company has also completed early-stage trials for another candidate, LTI-01, which targets loculated pleural effusions.
In recent developments, Rein has started its Phase 2 trial for LTI-03, with the first patient already dosed. This trial will evaluate the safety and effectiveness of the inhaled therapy across approximately 120 patients in a controlled setting. This step is crucial for the company's research and development efforts.